Rocky Mountain Spotted Fever : Symptoms

by CDC

(Page 3 of 4)

Rocky Mountain spotted fever can be very difficult to diagnose in its early stages, even by experienced physicians who are familiar with the disease.

Patients infected with R. rickettsii generally visit a physician in the first week of their illness, following an incubation period of about 5-10 days after a tick bite. The early clinical presentation of Rocky Mountain spotted fever is nonspecific and may resemble a variety of other infectious and non-infectious diseases.

The classic triad of findings for this disease are fever, rash, and history of tick bite. However, this combination is not always detected when the patient initially presents for care.

Initial Signs and Symptoms

Initial symptoms may include fever, nausea, vomiting, severe headache, muscle pain, lack of appetite.

The rash first appears 2-5 days after the onset of fever and is often not present or may be very subtle when the patient is initially seen by a physician. Younger patients usually develop the rash earlier than older patients. Most often it begins as small, flat, pink, non-itchy spots (macules) on the wrists, forearms, and ankles. These spots turn pale when pressure is applied and eventually become raised on the skin.

Later Signs and Symptoms

Later signs and symptoms include rash, abdominal pain, joint pain, diarrhea.

The characteristic red, spotted (petechial) rash of Rocky Mountain spotted fever is usually not seen until the sixth day or later after onset of symptoms, and this type of rash occurs in only 35% to 60% of patients with Rocky Mountain spotted fever. The rash involves the palms or soles in as many as 50% to 80% of patients; however, this distribution may not occur until later in the course of the disease. As many as 10% to 15% of patients may never develop a rash.

Abnormal Laboratory Findings

Abnormal laboratory findings seen in patients with Rocky Mountain spotted fever may include thrombocytopenia, hyponatremia, or elevated liver enzyme levels. See Laboratory Detection for more information on laboratory confirmation of Rocky Mountain spotted fever.

Hospitalization

Rocky Mountain spotted fever can be a very severe illness and patients often require hospitalization. Because R. rickettsii infects the cells lining blood vessels throughout the body, severe manifestations of this disease may involve the respiratory system, central nervous system, gastrointestinal system, or renal system. Host factors associated with severe or fatal Rocky Mountain spotted fever include advanced age, male sex, African-American race, chronic alcohol abuse, and glucose-6-phosphate dehydrogenase (G6PD) deficiency. Deficiency of G6PD is a sex-linked genetic condition which occurs with highest frequencies in people of African, Middle Eastern, and Southeast Asian origin; it affects approximately 12% of the U.S. African-American male population; deficiency of this enzyme is associated with a high proportion of severe cases of Rocky Mountain spotted fever. This is a rare clinical course that is often fatal within 5 days of onset of illness.

Long-term Health Problems

Long-term health problems following acute Rocky Mountain spotted fever infection include partial paralysis of the lower extremities, gangrene requiring amputation of fingers, toes, or arms or legs, hearing loss, loss of bowel or bladder control, movement disorders, and language disorders. These complications are most frequent in persons recovering from severe, life-threatening disease, often following lengthy hospitalizations.

Laboratory Detection

Although it is technically feasible, specific rapid laboratory confirmation of early Rocky Mountain spotted fever is rarely done. Therefore, treatment decisions should be based on epidemiologic and clinical clues, and should never be delayed while waiting for confirmation by laboratory results. Fundamental understanding of the signs, symptoms, and epidemiology of the disease is crucial in guiding requests for tests for Rocky Mountain spotted fever, sample collection and submission, and interpretation of laboratory results.

Routine clinical laboratory findings suggestive of Rocky Mountain spotted fever may include abnormal white blood cell count, thrombocytopenia, hyponatremia, or elevated liver enzyme levels (see Glossary for definitions of terms). Serologic assays are the most widely available and frequently used methods for confirming cases of Rocky Mountain spotted fever. The indirect immunofluorescence assay (IFA) (see figure) is generally considered the reference standard in Rocky Mountain spotted fever serology and is the test currently used by CDC and most state public health laboratories, but other well validated assays including ELISA, latex agglutination, and dot immunoassays can be used.

IFA can be used to detect either IgG or IgM antibodies. Blood samples taken early (acute) and late (convalescent) in the disease are the preferred specimens for evaluation. Most patients demonstrate increased IgM titers by the end of the first week of illness. Diagnostic levels of IgG antibody generally do not appear until 7-10 days after the onset of illness. It is important to consider the amount of time it takes for antibodies to appear when ordering laboratory tests, especially because most patients visit their physician relatively early in the course of the illness, before diagnostic antibody levels may be present. The value of testing two sequential serum or plasma samples together to show a rising antibody level is very important in confirming acute infection with rickettsial agents because antibody titers may persist in some individuals for years after the original exposure to any of a number rickettsial agents. IgG antibodies are more specific and reliable since other bacterial infections can also cause elevations in riskettsial IgM antibody titers.

The most rapid and specific diagnostic assays for Rocky Mountain spotted fever rely on molecular methods like PCR which can detect DNA present in 5-10 rickettsiae in a sample. While organisms can be detected in whole blood samples obtained at the acute onset of illness in a few hours, rickettsial DNA is most readily detected in fresh skin biopsies like those used in immunostaining procedures. PCR can also be done on the fixed tissues used in immunostaining, but it is less sensitive than with unfixed tissues. PCR methods can be R. rickettsii-specific but are usually confirmed by DNA sequencing of the amplified gene fragments. Consequently, this procedure is more specific than antibody-based methods which are often only genus or spotted fever group-specific. Specified diagnosis can also be confirmed by isolation of R. rickettsii from clinical samples like whole blood and biopsies. Materials can be shipped unfrozen or frozen and on dry ice to ensure optimal chances of isolation at the CDC. Isolation may require several weeks, but isolates are very important for investigating differences in the pathogenic properties and antimicrobial resistance of rickettsiae which cause disease in different parts of the United States.

Another approach to Rocky Mountain spotted fever diagnostics is immunostaining. This method is used by taking a skin biopsy of the rash from an infected patient prior to therapy or within the first 48 hours after antibiotic therapy has been started. Because rickettsiae are focally distributed in lesions of Rocky Mountain spotted fever, this test may not always detect the agent. Even in laboratories with expertise in performing this test, the sensitivity is only about 70% on biopsied tissues because of the scarcity of organisms in some samples. This assay may also be used to test tissues obtained at autopsy and has been used to confirm Rocky Mountain spotted fever in otherwise unexplained deaths (see figure). Immunostaining for spotted fever group rickettsiae is offered by the CDC, a few state health departments, and some university-based hospitals and commercial laboratories in the United States.

About the Author

www.cdc.gov
The Centers for Disease Control and Prevention (CDC) is one of the 13 major operating components of the Department of Health and Human Services (HHS), which is the principal agency in the United States government for protecting the health and safety of all Americans and for providing essential human services, especially for those people who are least able to help themselves.